


Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma

Supplementary Materials



Supplementary Figure 1: Cancer favoring affinity of CVV. (A) Biodistribution results at 2 weeks post-intraperitoneal injection of virus in HT29-bearing mice, showing that CVV selectively infected tumor masses. ($*p < 0.0001$). (B) Higher replication efficacy in cancer cells (Sk-Hep-1: human hepatocellular carcinoma cells, Lovo & HCT116: human colon cancer cells) than in normal cells (MEF: mouse embryonic fibroblast cells) ($*p < 0.0001$ vs MEF). (C) Cytotoxicity results of CVV on normal mouse embryonic stem cells (mES) vs human hepatocellular carcinoma, Sk-Hep-1 ($*p < 0.0001$ vs mES).